Sign in
Taking people in South AfricaNo phase

Testing a Peer Support Program for Men With TB and HIV

Tests a peer-support program for men with tuberculosis and HIV in South Africa.

Key facts

Who runs it
Arizona State University
Where
East London, South AfricaSee the site
Trial code
Registry title
Assessing the Feasibility of Coach Mpilo for Men With TB and HIV
Status
Recruiting
People taking part
240 people, planned
Started
1 Jun 2024
Planned end
31 Aug 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Coach Mpilo
Record updated
12 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men who are starting or restarting TB treatment in Buffalo City Metro (BCM) Health Districts, South Africa. One part is for men with TB only, another for men with TB and HIV.

Age
18 years or older
Sex
Men only
Disease stage
Starting TB treatment for the first time, or restarting TB treatment after being lost from care. One part of the trial is for men who also have HIV.
Earlier treatment
For the TB and HIV part: not taking antiretroviral therapy (ART) now.
Biomarker or test result
For the TB and HIV part: a positive HIV test.

Main reasons for not taking part

  • Not a man
  • Younger than 18 years
  • Does not live in BCM Health Districts
  • Cannot give written informed consent
  • TB and HIV part: HIV-negative or already on ART

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Aim 2: 1) men; 2) aged ≥18 years; 3) newly initiating (i.e., treatment naive) or re-initiating TBT after being loss-from-care per South African national guidelines; 4) live in BCM Health Districts; and 5) provide written informed consent
  • Aim 3: 1) men; 2) aged ≥18 years; 3) newly initiating (i.e., treatment naive) or re-initiating TBT after being loss-from-care per South African national guidelines; 4) HIV-positive; 5) Not on ART, 6) live in BCM Health Districts; and 7) provide written informed consent

Who cannot take part

  • Aim 2: 1) Not a man; 2) aged < 18 years; 3) not initiating (i.e., treatment naive) or not re-initiating TBT after being loss-from-care per South African national guidelines; 4) not live in BCM Health Districts; and 5) cannot provide written informed consent
  • Aim 3: 1) Not a man; 2) aged < 18 years; 3) not initiating (i.e., treatment naive) or not re-initiating TBT after being loss-from-care per South African national guidelines; 4) not HIV-positive; 5) on ART, 6) not live in BCM Health Districts; and 7) cannot provide written informed consent

This trial is currently available in South Africa.

  • Desmond Tutu Health FoundationEast London, South AfricaContact: Andrew Medina-MarinoTaking people

About the trial

What the trial wants to find out

Men are less likely to report TB-related symptoms, get diagnosed, smear convert, or complete treatment, suggesting that outcomes along the TB cascade are worse for men. Despite men's greater burden of TB and poorer treatment outcomes, no interventions have been developed to address these gendered disparities. Building on our preliminary research that identified men's preferences for a TB care support intervention, we identified Coach Mpilo (CM), a peer-support HIV treatment intervention that was developed by men for men in South Africa, and tailored for men TB infection. The aims of our study are to assess the feasibility of CM for men and assess secondary outcomes for treatment completion and HIV viral suppression to inform a Hybrid Type I intervention. In Aim 1, CM will be further tailored to men initiating TB treatment (CM-TB) and for with HIV co-infection (CM-TB/HIV). Using a mixed methods approach guided by ADAPT-IIT model, we will conduct interviews, CM simulations, and a pre-test to assess men's usability of CM-TB and CM-TB/HIV in this setting. We will conduct Aims 2 and 3 concurrently. In Aim 2, CM-TB will be evaluated to assess feasibility among men and secondary outcomes for retention in care and successful TB treatment (TBT) outcomes. Using a randomized controlled trial design, men (N=120) initiating TBT will be randomized to receive CM or clinic-based standard of care adherence support. The primary outcome is feasibility, acceptability, willingness and safety for men with secondary outcomes for completing TBT within 180 days per arm. In Aim 3, the feasibility of CM-TB/HIV for men (n=120) co-infected with TB and HIV will be assessed. The primary outcome is feasibility, acceptability, willingness and safety with secondary outcomes measured for proportion of men adherent to anti-retroviral therapy at TBT completion and with a suppressed viral (SVL) load 6 months post-ART initiation and post-TBT completion per study arm. If shown to be feasible, we will propose an randomized controlled trial to assess effectiveness in improving men's TB and HIV outcomes and adapted to improve men's health in the context of non-communicable diseases in South Africa and globally.

The 2 groups in the trial

  • Coach ImpiloTreatment being tested

    Peer support for TB and HIV treatment

    Treatment: Coach Mpilo

  • Standard of CareNo study treatment, for comparison

    Standard of care is treatment education and scheduled treatment pick up dates.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessing the Feasibility of Coach Mpilo for Men With TB and HIV in Eastern Cape, South Africa
Plain-language title
Testing a Peer Support Program for Men With TB and HIVGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 August 2025